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Available online 4 April 2012Botulinum neurotoxins (BoNT) are the most potent toxins known. Produced by Clostridium
botulinum, BoNTs are classified into seven, antigenically distinct serotypes, designated A–G.
The toxin acts to inhibit acetylcholine release, resulting in paralysis and death. Naturally
occurring foodborne disease is most often the result of improper canning of foods, while
wound botulism, associated with injection drug users, is on the rise. Because of its potency,
BoNTs have also been identified as targets for use by bioterrorists. The ‘gold standard’ of
detection of BoNTs is the mouse bioassay, an expensive and time consuming test that requires
specialized equipment and trained personnel. There is a need for a rapid, sensitive diagnostic
for BoNTs that could be used by minimally trained personnel in the event of a foodborne
outbreak or a bioterrorist threat. Here, we describe the use of a single lateral flow device (LFD)
that can detect and distinguish between BoNT/A and B, two of the four serotypes that are
known to intoxicate humans and together represent >80% of naturally occurring illness. The
device could detect as little as 5 ng/mL of purified BoNT/A and 10 ng/mL of BoNT/B in 2% and
1% milk, respectively. In undiluted apple juice, 25 ng/mL of BoNT/A and 10 ng/mL of BoNT/B
could be detected. No cross reactivity between BoNT/A and B antibodies was observed. The LFD
described here is easy to use, requires no specialized training or equipment, and can identify
and distinguish between BoNT/A and /B serotypes. These attributes make this rapid diagnostic
device a potentially valuable tool in the fields of food safety and homeland security.
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Clostridium botulinum is a spore-forming obligate anaer-
obe which occurs naturally in the soil and is the causative
agent of foodborne, wound and infant botulism (Shukla
and Sharma, 2005). Germinating spores of distinct strains
of C. botulinum produce and secrete different serotypes of
botulinum neurotoxin (BoNT), designated A–G, which can be
absorbed through mucosal surfaces (Swaminathan, 2011).
Aerosolization of BoNT as a means of dissemination can poseateral flow device;HC,
body;ELISA, enzyme-
riculture, ARS-WRRC,
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nasko).
 CC BY-NC-ND license. a bioterrorist threat (Shukla and Sharma, 2005; Arnon et al.,
2001; Eubanks et al., 2007).
BoNT is produced as a dichain polypeptide that is then
cleaved into a ~100 kDa heavy chain (HC) and a ~50 kDa
light chain (LC) (Montal, 2010). While the HC facilitates
entry of the toxin into neurons by endocytosis, the LC is a
metallopeptidase that cleaves soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs),
inhibiting acetylcholine release and resulting in flaccid
muscle paralysis (Montal, 2010; Schiavo et al., 2000). In
humans, a lethal dose intravenously or intramuscularly is
estimated at 1–2 ng/kg body weight; orally at 1 μg/kg and
10–12 ng/kg by inhalation (Arnon et al., 2001).
Given their potency, BoNTs have been employed as
therapeutics, as tools in basic science research, and as
weapons of biological warfare (Arnon et al., 2001; Shukla
and Sharma, 2005). The gold standard of detection of BoNTs
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of toxin (Sharma and Whiting, 2005). However, the assay
requires several days to complete, large numbers of animals
and can only be performed at a select number of laboratories
in the United States. To determine the serotype, a second,
independent neutralization assay is required. In the event of
a suspected BoNT contamination event, the mouse bioassay,
while extremely sensitive, does not meet the needs of
emergency responders. Therefore a rapid, sensitive, and
selective BoNT diagnostic test that can be field deployed
could be used to address suspect BoNT contamination.
A number of in vitro assays to detect BoNTs, including
ELISA kits, PCR-based methods and assays based on the
enzymatic activity of the toxin's light chain have been
developed (Chao et al., 2004; Wictome et al., 1999; Shone
et al., 1985). While some of these methods have comparable
sensitivity to the mouse bioassay, they still require trained
personnel and specialized equipment. In contrast, lateral flow
devices (LFDs) are simple, low cost alternatives that can be
easily deployed in the field and do not require specialized
training to operate or to interpret the results. LFDs can be
read without optical detection systems, are compact, and on
average have a long shelf life (Posthuma-Trumpie et al.,
2009; Warsinke, 2009; Ngom et al., 2010). While these
devices typically have less sensitivity than ELISA formats,
they do offer a method for rapid, simple assessment of
potential BoNT contamination to a multitude of personnel.
Our laboratory has developed several high affinity mono-
clonal antibodies (mAbs) that selectively recognize the BoNT/A
and /B serotypes. MAb F1-2, which recognizes the N-terminus
of the heavy chain of BoNT/A, has been extensively character-
ized and effectively employed as a capture antibody in a
sandwich ELISA (Scotcher et al., 2009; Stanker et al., 2008).We
have also previously described MCS-6-27, a BoNT/B-specific
mAb that binds the carboxyl portion of the HC and can be used
as a capture antibody in a sandwich ELISA (Scotcher et al.,
2010). Both these mAbs are highly specific for their respective
serotypes. Here, we describe the use of F1-2 and MCS-6-27
capture antibodies in combination with two novel detection
antibodies developed in our laboratory, F1-51, a BoNT/A HC-
specific mAb and BoB-92-32, a BoNT/B HC-specific MAb, in the
development of a rapid BoNT LFD.
Our LFD is capable of resolving BoNT/A and /B as two
independent colorimetric lines on a single strip, with
sensitivities >10 ng/mL for purified toxins and 10–500 ng/mL
in toxin fortified beverages. These results demonstrate the
capability of these mAb pairs to simultaneously detect BoNT
serotypes A and B on a simple and inexpensive immunochro-
matographic test strip. These devices could be used to aid in
BoNT detection by first responders or as part of commercial
food processing where natural contamination of C. botulinum
bacteria is suspect.
2. Materials and methods
2.1. Reagents and components
Botulinum toxins (BoNT) serotypes A and B where
purchased from Metabiologics, Inc (Madison, WI). Colloidal
gold (40 nm), PVC backing cards and plastic cassettes were
purchased from Diagnostic Consulting Network (Carlsbad,CA). Immunopore SP membrane, CF6 absorbent sink, Stan-
dard14 conjugate release pad and Fusion5 membrane were
purchased from GE Healthcare. Affinity purified donkey anti-
mouse IgG was obtained from Jackson ImmunoResearch
(West Grove, PA).
2.2. Monoclonal antibody production and puriﬁcation
The monoclonal antibodies F1-51 and BoB-92-32 were
produced as previously described (Scotcher et al., 2010;
Stanker et al., 2008). F1-51 was demonstrated to bind the HC
of BoNT/A while BoB-92-32 bound the HC of BoNT/B
(unpublished observation, LHS).
2.3. Synthesis of colloidal gold conjugated probe
The lowest possible concentration of mAb required for
stabilizing colloidal gold particles was prepared according to
previously published procedures with some modification
(Yokota, 2010). Briefly, each mAb was diluted to 5, 15, 20, 25,
30 and 40 μg/mL in water and the pH was adjusted to 9 with
0.2 M K2CO3. Next, 0.5 mL of colloidal gold (pH 9) was added
to 100 μL of each antibody dilution and incubated for 10 min
at room temperature. Next, 100 μL of 10% NaCl was added to
each tube and the change in color was assessed. The lowest
antibody concentration with no color change represented the
optimal concentration for stabilizing the gold sol. Antibody-
gold conjugates were prepared using the determined anti-
body concentration. Unconjugated antibody was removed by
centrifugation at 15,000 ×g at 4 °C for 30 min. Conjugates
were stored in buffer A (50 mM phosphate, pH 9, 0.1% tween-
20, 1% BSA) at 4 °C.
2.4. Assembly of lateral ﬂow device
Capture antibodies were diluted in 10 mM phosphate
buffer with 3% v/v methanol and applied to the membrane at
1 mg/mL using a BioJet Quanti Dispenser (BioDot, Irvine, CA),
dried at 37 °C for 30 min, then blocked in 10 mM PBS, 0.1%
fish gelatin, 1% BSA and 0.5% Triton X-100 for 1 h. The
blocked membrane was dried for 30 min at 37 °C and
assembled on to the backing card with a 2 mm overlap by
the absorbent sink. The conjugation pads were prepared by
immersion of gold conjugated antibodies diluted in buffer
containing 50 mM phosphate, 1% BSA, 5% sucrose and 0.1%
tween-20. Conjugation pads were then dried for 30 min at
37 °C and fixed, with an ~2 mm overlap with the nitrocellu-
lose, on the backing card. Finally, Fusion5 membrane was
employed as the sample pad with an ~2 mm overlap with the
conjugation pad. The entire assembly was housed in a plastic
cassette (Fig. 1).
2.5. Preparation of BoNT-spiked beverages
Whole, 2% and 1% milk were obtained from a local grocery
store. Apple juice and orange juice were obtained from a
refrigerated vending machine. Spiked milk samples were
assessed by two methods: (1) following a 10-fold dilution
with double deionized water and (2) following centrifuga-
tion at 12,000 ×g at 4 °C for 20 min to remove fatty content.
Following spike with toxin, orange and apple juice were both
Fig. 1. Schematic of lateral flow device (LFD). The device consists of a nitrocellulose membrane to which an anti-mouse IgG (control capture line) and C. botulinum
serotype specific capture antibodies (BoNT/A and BoNT/B capture line) are immobilized. Fixed to the lower end of the membrane is a conjugation pad containing
immobilized anti-BoNT gold-conjugated antibody. A sample pad overlays the conjugation pad. At the upper end of the membrane is an absorbent sink which acts
to facilitate capillary flow through the device. The entire device is fixed to a backing card and held in a plastic housing. Sample is added at the sample port,
absorbed into the sample pad and flows by capillary action through the conjugation pad. If toxin is present it binds the gold-conjugated detector antibody, and
together they flow to the test capture line where the immobilized capture antibody binds the antigen, resulting in the resolution of a red line obvious to visual
inspection. The sample continues to flow over the control capture line which binds remaining gold conjugated detector antibody (either bound or unbound to
toxin) resulting in a red line that validates proper test function. Remaining fluid and sample is absorbed by the absorbent sink at the end of the device. The actual
LFD (right) shows an example of positive detection of BoNT/A and /B serotypes with the control line.
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tested by two methods: (1) following a 2-fold dilution with
phosphate buffer; and (2) following centrifugation to removeFig. 2. Lateral flow detection of BoNT serotypes. A serial dilution (100 ng/mL to 0.2
Fifty microliters of diluted BoNT/A or BoNT/B was then applied to lateral flow strips p
BoNT/B-specific mAb MCS-6-27 capture antibody (panel B), respectively. The abs
phosphate buffer (PB) alone to the device served as control for non-specific binding
conjugated antibody by immobilized control or test antibody; − indicates no reso
Arrow indicates the direction of sample flow.pulp. Apple juice samples were tested: (1) directly after
spiking and; (2) following a 2-fold dilution with phosphate
buffer.ng/mL) of either BoNT/A or BoNT/B was prepared in phosphate buffer (PB).
repared with either BoNT/A-specific mAb F1-2 capture antibody (panel A) or
ence of a line in the test zone (BoNT/A or BoNT/B) following addition of
. C is the location of anti-mouse control line. + indicates resolution of gold-
lution of gold-conjugated antibody by immobilized control or test antibody.
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3.1. Detection of BoNT/A and /B by lateral ﬂow
Here, we investigated the application of mAb capture/
detector pairs for BoNT/A and BoNT/B, developed previously
in our laboratory, in a LFD. For the BoNT/A LFD, F1-2 and a
control goat-anti mouse IgG were separately immobilized on
a nitrocellulose membrane at 1 mg/mL using a BioJet Quanti
Dispenser. The F1-51 mAb was conjugated to 40 nm gold
particles and applied by immersion onto a conjugate release
pad. A serial dilution of purified toxin, ranging from 100 to
0.2 ng/mL, was prepared in a phosphate buffer, and the assay
was initiated by the application of diluted toxin (50 μL) to the
sample pad (Fig. 2). A visible red line was resolved in ~10–
15 min. As shown in Fig. 2A, detection of purified BoNT/A was
easily visualized at concentrations of 100 to 5 ng/mL, and
weakly visible at 1 and 0.2 ng/mL. No reactivity was observed
when purified BoNT/B was applied at 100 ng/mL (data not
shown) or with buffer alone. These results demonstrate the
suitability of mAbs F1-2 and F1-51 for use in a sensitive and
selective LFD to detect BoNT/A.
A BoNT/B LFD was also developed using mAbs devel-
oped in our laboratory. Anti-BoNT/B monoclonal antibody
MCS-6-27 and control goat anti-mouse IgG were separately
immobilized at 1 mg/mL onnitrocellulose, andmAb BoB-92-32
was employed as the detector antibody. A serial dilution, again
ranging from 100 to 0.2 ng/mL of purified BoNT/B was
evaluated. With a limit of detection of 5 ng/mL, the BoNT/B
LFD was not as sensitive as the BoNT/A device (Fig. 2B).
Increasing the concentration of the immobilized capture
antibody did not improve the sensitivity of the assay (data
not shown), however the BoNT/B LFD demonstrated high
specificity, showing no reactivity with BoNT/A toxin (data not
shown).
3.2. A single immunochromatographic strip to detect BoNT/A
and /B
As individual assays, the monoclonal antibody pairs for
BoNT/A and /B demonstrated high specificity for their respec-
tive serotypes. As such, we sought to determine if they could be
used together in a single LFD capable of detecting both BoNT/A
and /B. Control goat anti-mouse antiserum, mAbs F1-2 and
MCS-6-27 antibodies were immobilized on a nitrocellulose
strip each separated by ~4 mm. To demonstrate the specificity
of the antibodies employed as capture and detector reagents,
three different sets of conjugation pads were prepared
containing F1-51 alone, BoB-92-32 alone and F1-51 and BoB-
92-32 together at a ratio of 1:2. Each set of conjugation pads
were tested with BoNT/A alone, BoNT/B alone, BoNT/A and /B
together or with phosphate buffer (PB) alone. All toxins were
used at a concentration of 100 ng/mL. As shown in Fig. 3, all
capture and detector antibodies demonstrated a high level of
specificity. BoNT/A was detected only when gold-conjugated
F1-51 was present on the conjugation pad (Fig. 3A and C).
When BoNT/Awas applied to a conjugation pad containing only
BoB-92-32, the toxin was not detected (Fig. 3B), demonstrating
that BoNT/A toxin is not recognized by the BoNT/B-specific
detector antibody. These results are consistent with those
observed in the single serotype LFDs described above. Thesame held true for the detection of BoNT/B. BoNT/B was
detected only when BoB-92-32 was present on the conjugation
pad (Fig. 3B and C) and was not recognized by the BoNT/A
detector antibody (Fig. 3A). These results demonstrate that the
antibodies used as capture and detector antibodies for this LFD
can distinguish between BoNT/A and /B serotypes and are
consistentwith earlier ELISA observations (Scotcher et al., 2010;
Stanker et al., 2008; Yokota, 2010).
Finally, a titration from100 ng/mL of each toxin to 0.2 ng/mL
revealed thatwith the dual detector strip, a limit of detection for
both BoNT/A and /B was reached at approximately 10 ng/mL of
toxin (data not shown). These results are the first to demon-
strate sensitive and selective detection of both BoNT/A and /B
using a single lateral flow device.
3.3. Detection of BoNT in milk, apple and orange juice
To determine the utility of the dual BoNT/A/B LFD in
real-world samples, we spiked whole, 2%, and 1% milk with
BoNT/A and /B (500 ng/mL of each toxin) then serially
diluted them with the appropriate milk to 100, 50, 25, 10 and
5 ng/mL. Prior to testing, spiked milk samples were further
diluted 10-foldwith double deionizedwater.With these diluted
samples, the LFD showed the greatest sensitivity with 1% milk
samples achieving a limit of detection of 100 ng/mL (concen-
tration before dilution) for both BoNT/A and B (Table 1). In
contrast, BoNT/A could be detected in 2% and whole milk at a
spike level of 100 and 500 ng/mL, respectively. BoNT/B could
be detected at a spike level of 500 ng/mL in 2% milk, but could
not be detected in whole milk.
Given that the LFD demonstrated the greatest sensitivity
with the least fatty milk samples, we attempted to further
reduce the fat content of the milk samples by centrifugation.
Whole, 2% and 1% milk samples were spiked at 1 μg/mL of
each toxin, and then centrifuged at 4 °C. The resulting fatty
layer was aspirated and serial dilutions of the spiked samples
were prepared in defatted milk and applied directly to the
LFD. As expected, removal of the fatty content greatly
improved the sensitivity of the LFD. BoNT/A was detected at
10 ng/mL in defatted whole and defatted 1% milk and at a
limit of 5 ng/mL in defatted 2% milk (Table 1). BoNT/B was
detected at 25 ng/mL in defatted whole milk and at 10 ng/mL
in both 2% and 1% defatted milk (Table 1). It should be noted
that these defatted samples flowed faster and more evenly
than the diluted milk samples. Overall, for the milk samples,
fat removal versus sample dilution resulted in greater
sensitivity.
BoNT/A/B spiked (500 ng/mL) apple (Fig. 4A–B) and
orange juices (Fig. 4C–D) were also evaluated with our LFD.
Following the spike with BoNT/A and B, both juices were
brought to a neutral pH using 1 M NaOH, then serially diluted
from 1 μg/mL to 10 ng/mL in neutralized juice. Apple juice
was directly tested, and a limit of detection of 25 ng/mL and
10 ng/mL for BoNT/A and /B, respectively was achieved.
Dilution of the spiked apple juice with a phosphate buffer did
not improve assay performance for either BoNT/A or /B. The
lowest level of detection following dilution was from samples
with an initial spike of 50 ng/mL for BoNT/A and 10 ng/mL for
BoNT/B.
Orange juice samples were diluted 2-fold with a phosphate
buffer prior to testing. Both BoNT/A and B could be detected
Fig. 3. A single device for detection of both BoNT/A and B. Lateral flow strips each with control, anti-BoNT/A and anti-BoNT/B capture lines were prepared with
gold conjugated BoNT/A specific mAb F1-51 (panel A), gold conjugated BoNT/B specific mAb BoB-92-32 (panel B) or both gold conjugated BoNT/A and B mAbs
(panel C). Samples containing BoNT serotype-A alone (Lane A), BoNT serotype-B alone (Lane B), a mixture of BoNT Serotype-A and -B (Lane A+B) or sample
phosphate buffer alone (Lane PB) were applied. + indicates resolution of gold-conjugated antibody by immobilized control or test antibody; − indicates no
resolution of gold-conjugated antibody by immobilized control or test antibody.
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The limit of detection following centrifugation remained at
25 ng/mL for both BoNT/A and B. Thus removal of particulate
pulp in orange juice did not improve the sensitivity of the assay
for either toxin.Table 1
Limit of detection of BoNT/A and B in spiked beverages using a LFD.
BoNT/A (ng/mL) BoNT/B (ng/mL)
Whole milk 500a Not detected
Whole milk, defatted 10 25
2% milk 100a 500a
2% milk, defatted 5 10
1% milk 100a 100a
1% milk, defatted 10 10
Apple juice 25 10
Apple juice, diluted 50b 10b
Orange juice, diluted 25b 25b
Orange juice, supernatant 25 25
a Spike level represents the amount of BoNT/A and B before a 10-fold
dilution of the sample.
b Spike level represents the amount of BoNT/A and B before a two-fold
dilution of the sample.4. Discussion
Naturally occurring C. botulinum infection in the United
States is a rare, but a serious condition. Foodborne botulism
occurs sporadically throughout the country and is most often
related to home-canned food, where the bacteria proliferate
within the anaerobic environment (Sobel, 2005). A recent
epidemiological study of wound botulism noted a 20-fold rise
in known cases over a 10 year period, mostly attributed to
injection drug users (Werner et al., 2000). Finally, attempts
by bioterrorists to weaponize BoNT have been well docu-
mented in many countries (Arnon et al., 2001; Swaminathan,
2011). The most recent occurrence was in Japan, when, over
a five year period, three attempts were made to disseminate
aerosolized toxin in downtown Tokyo and at a U.S. military
base in Japan (Arnon et al., 2001).
Given the public health threat of BoNTs many interna-
tional groups have sought to develop alternative diagnostic
assays to offset the labor-intensive mouse bioassay. The
majority of these efforts focus on improving the sensitivity
and selectivity of antibody based immunoassays. The use of
BoNT serotype specific antibodies as part of diagnostic
immunoassays has proven capable of resolving specific BoNT
Fig. 4. Representative LFD for detection of BoNT Serotype-A and -B in spiked beverages. Undiluted apple juice (A), diluted apple juice (B), centrifuged orange juice
(C) and diluted orange juice (D) all with an initial spike level of 500 ng/mL of BoNT/A and /B are shown. Fifty microliters of diluted sample was added at the
sample port.
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2000; Sharma et al., 2006; Brunt et al., 2010; Brooks et al.,
2011). Still others have exploited the endopeptidase activity of
the toxin for detection using in vitro assays (Wictome et al.,
1999; Rasooly and Do, 2008). While many of these assays
approach the sensitivity of themouse bioassay they still require
specialized equipment and trained personnel. The develop-
ment of highly sensitive BoNT detection assays as part of an
overall bio-defense strategy should also include inexpen-
sive portable diagnostic devices with simple visual verifi-
cation for use by minimally trained personnel. A rapid
colorimetric BoNT LFD would be of value to both emergency
first responders in the assessment of possible contamina-
tion and to food processing facilities as part of routine
quality assurance. A simple inexpensive BoNT LFD offers the
potential to meet the need for rapid BoNT detection from a
variety of substrates and settings.
Here we report the design and use of a single lateral flow
device capable of detecting and distinguishing between
BoNT/A and /B. The LFD demonstrated the greatest sensitivity
for BoNT/A, detecting as little as 5 ng/mL in 2%, defatted milk.
BoNT/B could be detected down to 10 ng/mL in spiked 1% and
2% defatted milk and undiluted apple juice. In contrast to
currently available commercial LFDs, which utilize polyclonal
antibodies that are cross reactive for BoNT/A and /B, our
device can distinguish between BoNT/A and /B serotypes as it
uses two sets of highly specific monoclonal antibody pairs.
Recently, Sharma et al. evaluated the Alexeter Technologies
BoNT/A/B strip, which cannot distinguish between the two
serotypes (Sharma et al., 2005). In these studies, the Alexeter
strip demonstrated a lower limit of detection of 100 ng/mL
when spiked milk products were diluted and 10 ng/mL when
they were defatted. The device developed here achieved
similar sensitivities in milk, but outperformed the Alexeter
Technologies strip in spiked orange juice samples by four-fold, detecting both BoNT/A and /B in orange juice spiked at
25 ng/mL. Gessler et al. evaluated the BioThreat Alert BoNT/
A/B test strip, available from Tetracore, with a number of
spiked clinical samples (Gessler et al., 2007). Interestingly,
the test could not detect purified toxin, suggesting that the
antibodies used in the strip are likely specific for epitopes of
the BoNT complex and not the actual toxin itself. Both
capture antibodies used in our device, F1-2 and MCS-6-27,
recognize specific epitopes on the heavy chains of BoNT/A
and B, respectively (Scotcher et al., 2009, 2010), and are thus
capable of detecting purified toxin as well as crude toxin
preparations.
Colloidal gold labeling of antibodies is one of the most
widely employed strategies for building lateral flow devices
because it is relatively inexpensive and very stable in its dried
form. While we employed gold-labeled antibodies in the
system described here, colored latex beads could alternatively
be incorporated and would provide a color-coded result that
would further simplify interpretation of the results. Studies are
in progress to add other serotype specific antibodies, such as
BoNT/E and /F, that will add further value to our detection
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